About Cerecor
Cerecor is a company based in Baltimore (United States) founded in 2011.. Cerecor has raised $45.2 million across 6 funding rounds from investors including NIH, Hercules Capital and Maxim Group. The company has 20 employees as of December 31, 2022. Cerecor has completed 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER and Trxpharma. Cerecor offers products and services including AVTX-009, Quisovalimab, and AVTX-008. Cerecor operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alto Neuroscience, among others.
- Headquarter Baltimore, United States
- Employees 20 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avalo Therapeutics, Inc.
-
Annual Revenue
$18.05 M234as on Dec 31, 2022
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45.2 M (USD)
in 6 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Apr 28, 2017
-
Investors
NIH
& 6 more
-
Employee Count
20
as on Dec 31, 2022
-
Investments & Acquisitions
Aevi Genomic Medicine
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cerecor
Cerecor offers a comprehensive portfolio of products and services, including AVTX-009, Quisovalimab, and AVTX-008. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets inflammatory diseases via anti-IL-1β for immune dysregulation
Anti-LIGHT mAb for treating immune dysregulation disorders
BTLA agonist to modulate immune responses in therapies
Unlock access to complete
Unlock access to complete
Funding Insights of Cerecor
Cerecor has successfully raised a total of $45.2M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(04 Apr 2012)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2017 | Amount | Post-IPO - Cerecor | Valuation |
investors |
|
| Sep, 2016 | Amount | Post-IPO - Cerecor | Valuation |
investors |
|
| Apr, 2016 | Amount | Grant - Cerecor | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cerecor
Cerecor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Hercules Capital and Maxim Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cerecor
Cerecor has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aevi Genomic Medicine, Karbinal ER and Trxpharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Information on allergy drugs is provided through an online platform.
|
2011 | ||||
|
Therapeutics for rare diseases in neurology and hematology are developed.
|
2001 | ||||
|
-
|
0 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Cerecor
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cerecor Comparisons
Competitors of Cerecor
Cerecor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alto Neuroscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cerecor
Frequently Asked Questions about Cerecor
When was Cerecor founded?
Cerecor was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is Cerecor located?
Cerecor is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Is Cerecor a funded company?
Cerecor is a funded company, having raised a total of $45.2M across 6 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Apr 04, 2012.
How many employees does Cerecor have?
As of Dec 31, 2022, the latest employee count at Cerecor is 20.
What is the annual revenue of Cerecor?
Annual revenue of Cerecor is $18.05M as on Dec 31, 2022.
What does Cerecor do?
Founded in 2011, Cerecor operates from Baltimore, United States, within the biotechnology sector. Focus is placed on developing treatments for immunological and neurological conditions. The pipeline encompasses CERC-002, targeted at pediatric Crohns disease; CERC-007, aimed at inflammatory arthritis and multiple myeloma; and CERC-802 along with CERC-803, directed toward congenital disorders. Efforts center on advancing these therapeutic candidates through clinical stages.
Who are the top competitors of Cerecor?
Cerecor's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alto Neuroscience.
What products or services does Cerecor offer?
Cerecor offers AVTX-009, Quisovalimab, and AVTX-008.
How many acquisitions has Cerecor made?
Cerecor has made 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER, and Trxpharma.
Who are Cerecor's investors?
Cerecor has 7 investors. Key investors include NIH, Hercules Capital, Maxim Group, Armistice Capital, and Turmeric Acquisition Corp.